Q-omics provides the consensus-scored CFAP94 profile across patient tissues and cancer cell-line models. CFAP94 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CFAP94 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, CFAP94 RNA expression shows 18,990 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where CFAP94 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP94 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP94 survival associations across molecular data types. CFAP94 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP94 RNA expression–survival associations across cancer types. High CFAP94 expression shows unfavorable associations in LGG, but favorable associations in KIRC, BRCA, ACC, KIRP and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CFAP94 RNA expression.
This table summarizes CFAP94 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CFAP94. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP94 shows lower tumor expression in KICH, THCA, LUSC, LUAD and BLCA and higher tumor expression in CHOL. The KICH box plot shows higher CFAP94 RNA expression in normal versus tumor tissue (log2 FC = −2.357, t-test p < 0.001).
This table shows molecular features associated with CFAP94 in patient tissues and cancer cell lines. In patient samples, CFAP94 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP94 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
